SCHEMBL5534616

SCHEMBL5534616

[CH2]CCc1ccc(Oc2ccc(OC(F)(F)F)cc2)cc1

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 2/20 0.49
LTA4H P09960 1/20 0.49
DAO P14920 1/20 0.44
GPR84 Q9NQS5 1/20 0.42
ALDH1A1 P00352 1/20 0.41
TSHR P16473 1/20 0.41
SLC6A4 P31645 6/20 0.41
SLC6A3 Q01959 5/20 0.41
MMP2 P08253 1/20 0.40
MMP9 P14780 1/20 0.40
MMP14 P50281 1/20 0.40
KCNH2 Q12809 1/20 0.40
SLC6A2 P23975 1/20 0.40
NR3C1 P04150 1/20 0.39
FAAH O00519 1/20 0.39
CETP P11597 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1046754 0.94 DAO (0.47) EPHX2LTA4HDAOGPR84ALDH1A1
SCHEMBL5535120 0.89 EPHX2 (0.47) EPHX2LTA4HDAOGPR84ALDH1A1
SCHEMBL5545112 0.89 DAO (0.44) EPHX2LTA4HDAOGPR84ALDH1A1
SCHEMBL5542307 0.86 LTA4H (0.45) EPHX2LTA4HDAOGPR84ALDH1A1
SCHEMBL6002645 0.85 EPHX2 (0.44) EPHX2LTA4HDAOALDH1A1TSHR
SCHEMBL5544157 0.84 MAPK14 (0.48) EPHX2LTA4HDAONR3C1CETP
SCHEMBL1119469 0.83 DAO (0.45) EPHX2LTA4HDAOGPR84ALDH1A1
SCHEMBL22167226 0.81 EPHX2 (0.49) EPHX2LTA4HDAOGPR84ALDH1A1
SCHEMBL8513609 0.81 LTA4H (0.49) EPHX2LTA4HDAOGPR84ALDH1A1
SCHEMBL5544769 0.81 TAAR1 (0.50) EPHX2LTA4H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 EPHX2 3662/4885LTA4H 3452/4885DAO 1115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.